Third Rock Ventures II L.P. 13D and 13G filings for Jounce Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:06 pm Sale | 2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE | Third Rock Ventures II L.P. | 335,533 0.600% | -3,794,934 (-91.88%) | Filing |
| 2022-02-14 4:52 pm Sale | 2021-12-31 | 13G | Jounce Therapeutics, Inc. JNCE | Third Rock Ventures II L.P. | 4,130,467 8.100% | -8,209,361 (-66.53%) | Filing |
| 2021-02-16 4:06 pm Sale | 2020-12-31 | 13G | Jounce Therapeutics, Inc. JNCE | Third Rock Ventures II L.P. | 12,339,828 31.000% | -939,292 (-7.07%) | Filing |